Therapy Areas: AIDS & HIV
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
9 May 2023 - - US-based pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop (C1 Workshop) in Budapest, Hungary, the company said.

The following presentations occurred at the 2023 C1 Workshop:

Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA (oral presentation)

HAE Patients Decision to Carry On-demand Treatment When Away from Home: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON Canada (oral presentation)

Route of Administration Preferences of People with Hereditary Angioedema for On-demand Treatment: A US-based Qualitative Study: Laurence Bouillet, Internal Medicine, Grenoble Alpes University, National Reference Center for Angioedema, Grenoble, France (poster presentation).

In the first oral presentation, KalVista presented data providing the rationale for the sebetralstat regimen for short-term prophylaxis for medical and dental procedures in people living with hereditary angioedema in the phase 3 KONFIDENT-S trial, which is an ongoing, up to 2-year, open-label extension of the phase 3 KONFIDENT trial.

The second oral presentation was based on real-world survey data collected from people with HAE and showed that only one-third of patients always carry on-demand attack treatment with them when away from home.

Of note, those that did not carry treatment would routinely travel for several hours without it for a variety of reasons, including a preference to treat with injectables at home.

The poster presentation, based on qualitative interviews with adolescents and adults with HAE, demonstrated that both groups had a strong preference for oral medication for on-demand treatment of attacks over self-administered injectable treatments when efficacy and safety profiles were similar.

Links to all posters and oral presentations can be found on the KalVista website under "Publications."

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need.

KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.